Leveraging AI to Transform Neurodegenerative Drug Development From Discovery to Clinical Research
By Anne-Marie Nagy, Ph.D.
VP, Head of Internal Medicine & Neuroscience
Neurodegenerative diseases continue to present one of the greatest challenges in drug development due to their biological complexity, unpredictable progression, and historically high trial failure rates. This white paper explores how artificial intelligence (AI) is being applied across every phase of the drug development lifecycle—from discovery to post-market surveillance—to accelerate progress and increase clinical success rates in CNS indications.
Download our white paper to discover:
- AI enhances early discovery and biomarker validation
- Patient recruitment and stratification are improving through AI-driven analytics
- Protocol design and adaptation benefit from predictive modeling
- Natural language processing (NLP) and machine learning enable real-time data mining
- AI is fostering regulatory innovation and data integrity
Learn more about our related services and resources:
Download the White Paper
About the Author
Anne-Marie Nagy
Anne-Marie joined TFS in September 2021 as Vice President, Head of Internal Medicine and Neuroscience and is responsible for supporting the project delivery of all internal medicine and neurology programs. Within her role, Anne-Marie manages a global team of experts ranging from physicians to clinical specialists delivering full-service clinical development programs and services for pharmaceutical and biotechnology customers.
Connect with Us
Contact us today to discover how TFS can be your strategic CRO partner in clinical development.
Learn More About Our Neuroscience Expertise
Rare Neurological Disease Trials: Smarter Design with Natural History, External Controls, and Real-World Evidence
Neuroscience Clinical Research Trends in 2025: How Innovative CROs are Shaping the Future of Neurological Trials
